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Abstract
Background: For CAM to feature prominently in health care decision-making there is a need to expand the
evidence-base and to further incorporate economic evaluation into research priorities.
In a world of scarce health care resources and an emphasis on efficiency and clinical efficacy, CAM, as indeed do
all other treatments, requires rigorous evaluation to be considered in budget decision-making.
Methods: Economic evaluation provides the tools to measure the costs and health consequences of CAM
interventions and thereby inform decision making. This article offers CAM researchers an introductory framework
for understanding, undertaking and disseminating economic evaluation. The types of economic evaluation
available for the study of CAM are discussed, and decision modelling is introduced as a method for economic
evaluation with much potential for use in CAM. Two types of decision models are introduced, decision trees and
Markov models, along with a worked example of how each method is used to examine costs and health
consequences. This is followed by a discussion of how this information is used by decision makers.
Conclusions: Undoubtedly, economic evaluation methods form an important part of health care decision making.
Without formal training it can seem a daunting task to consider economic evaluation, however, multidisciplinary
teams provide an opportunity for health economists, CAM practitioners and other interested researchers, to work
together to further develop the economic evaluation of CAM.
Background
Economic evaluation is discussed often in the conven-
tional health care literature and it is well established
that clinical efficacy and cost-effectiveness evidence are
necessary to assist health care decision-making within
the confines of finite health budgets. Research examin-
ing the safety and efficacy of Complementary and Alter-
native Medicine (CAM) is rapidly growing [1], and there
appears to be a potential role for CAM in a number of
treatment areas [2]. In order for CAM to be extensively
considered in health care decision-making there is a
need to expand the evidence-base for these medicines
and therapies and for the CAM research community to
further incorporate economic evaluation into research
priorities (alongside developing a broader health services
research agenda) [3]. The aims of this article are to dis-
cuss the need for economic evaluation, outline the types
of economic evaluation available for the study of CAM,
and introduce decision modelling as one flexible method
for economic evaluation with much potential for use in
examining and assessing CAM. Our discussion offers
CAM researchers an introductory framework for under-
standing, undertaking and disseminating economic eva-
luation. It is hoped that this paper will help fuel
enthusiasm and develop early capacity towards produ-
cing much needed rigorous economic evaluation of
CAM.
A Growing Need for Economic Evaluation in CAM
In a world of scarce health care resources and an
emphasis on efficiency and clinical efficacy, CAM (like
all treatments) requires rigorous evaluation if it is to be
fully considered in budget decision-making [4]. While
the research base for CAM is small relative to that for
conventional medicine, it is growing [1] and evidence
shows some CAM therapies are safe and effective [2].
A logical next step is to examine the ‘real world’ impact
of CAM; whether it offers value for money in
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ments. Any informed attempt to consider CAM provi-
sion as a core component of a comprehensive and
integrated health care system requires a focus upon
associated change to costs and health benefits [5,6]. Eco-
nomic evaluation methods provide the tools to measure
the costs and health consequences of CAM interven-
tions and thereby inform decision making.
The number of published health economic evaluations
in Australia and around the world is rapidly increasing.
Some researchers have identified economic evaluation
and its importance in relation to CAM [7,8] and there
are several systematic reviews which have examined the
number and quality of economic evaluations which cur-
rently exist in the CAM literature [9,10]. One recent
systematic review concluded there was a limited number
of evaluations of sufficient quality to draw general con-
clusions. Nevertheless, this review did consider a small
number of treatment areas as cost-effective compared
with conventional care, including the use of acupuncture
for migraines, manual therapy for neck pain, and spa
therapy for Parkinson’s disease. There was also evidence
to suggest CAM can be considered cost effective in a
complementary role in the treatment of some condi-
tions, for example complementary guided imagery for
cardiac surgery patients and complementary relaxation
therapy for patients with a previous myocardial infarc-
tion. It is perhaps easier to consider that CAM
approaches which are substitutes for conventional care
a r em o r el i k e l yt ob ec o s t - e f f e c t i v e ,h o w e v e r ,t h e r ei s
also evidence for CAM in a complementary role, despite
the addition of another treatment [6].
CAM evaluation does face potential challenges given
CAM’s different philosophical tenets when compared to
conventional medicine [11]. Treatment is often a com-
plex combination of several therapies tailored to the
individual [1], and the therapeutic effects of CAM are
often small, difficult to quantify and can occur over a
long period, whether administered as a stand alone
treatment or provided in addition to conventional medi-
cine. It is important to use the evaluation framework
whilst incorporating CAM-sensitive outcome measures
and to focus on the development of outcome measures
which capture the effects of CAM and study designs
which allow these outcomes to be examined. As such, it
is essential that this area be developed through colla-
boration between CAM practitioners and health services
researchers, to ensure economic evaluation research is
conducted in a manner which captures the broad bene-
fits of CAM.
In order to address the gap in research and help
others develop capacity in this significant area of CAM-
related inquiry, this paper provides an overview of eco-
nomic evaluation, and introduces the concept of
decision modelling as a method for economic evaluation
ideal for CAM.
Methods
Economic Evaluation for CAM
Different schools of thought in economic evaluation
There are two schools of thought in economic evalua-
tion, described in brief here due to extensive description
elsewhere in the CAM literature [1,6,8]. Costs are con-
sistently measured in monetary units, benefits are mea-
sured in different ways. Cost-benefit analysis (CBA)
summarises benefits in monetary values, enabling a
direct comparison between costs and outcomes. Using
CBA anything can be compared and health goals can be
compared with non-health goals. Individual preferences
are valued, often using the concept of willingness to pay
(WTP). CBA can be difficult to apply as giving health
outcomes monetary value can be problematic [12]. In
contrast, cost effectiveness analysis (CEA) and cost-uti-
lity analysis (CUA) are useful for allocating a fixed
health budget between competing treatments to maxi-
mise health improvements. CEA is used when programs
or treatments have a common outcome of interest to
compare. CUA is similar, except for a focus on the qual-
ity of the outcome, incorporating a sense of value or
preference as captured by the use of quality adjusted life
years (QALYs) [13,14]. The concept of the QALY was
designed to capture changes to both quantity and qual-
ity of life from a treatment or intervention [15]. QALYs
are calculated by weighting the extra time spent alive
because of an intervention with a utility value, known as
the QALY weight. It represents a preference based
valuation of a particular health state and allows both
quantity and quality to be summarised in a single mea-
sure [15,16]. The scale of QALY weights is for death to
equal 0 and perfect health to equal 1. Two extra years
of life in a state value at 0.7 is equal to 1.4 QALYs.
As an example of utility weights, a recently published
study derived estimates for the stages of chronic heart
failure, New York Heart Association (NYHA) class I, II,
III, and IV had weights of 0.90, 0.83, 0.74, and 0.60
respectively. NYHA class I is an asymptomatic stage of
heart failure, and so the value of that particular state is
close to perfect health. On the other hand NYHA class
IV is associated with persistent symptoms despite opti-
mal medical treatment, and therefore the value of that
state is further from perfect health [17]. The suitability
of QALYs as a measure of outcome is a complex issue
which has been discussed in both conventional and
CAM literature [1,4,14,18-20]. Currently available full
economic evaluations for CAM have all utilised CEA or
CUA, perhaps because they are more easily applied than
CBA requiring the valuation of health in monetary
terms. For a comprehensive discussion of CBA versus
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report written by Alan Krupnick [21].
Decision analytic modelling has become increasingly
popular as a method for the economic evaluation of
health care. It is a flexible method which has not been
previously discussed in reference to CAM. A full cri-
tique of this approach is beyond the scope of this paper,
but can be found in the literature [22]. Randomised clin-
ical trials (RCTs) can provide valuable information
about treatment effectiveness and have often been used
as the single source of data for economic decision mak-
ing [23]. There are limitations to using only RCT data
for economic evaluation. Decisions are often made
between multiple competing options, which are unlikely
to have been compared in a single trial. RCTs are often
b a s e do nv e r ys t r i c tc r i t e r i at h a tr e d u c e st h ea b i l i t yt o
generalise the results. Often not all of the factors of
interest are measured, intermediate measures are often
used instead of final endpoints; and the timeframe for
RCTs is often short, whereas lifetime costs are impor-
tant when compiling economic evidence [24].
Decision analytic modelling provides an opportunity
t ou s em u l t i p l ed a t as o u r c e sa n de x t r a p o l a t eb e y o n d
the limits of current clinical evidence in order to
include alternative interventions [25]. Other benefits
include the provision of a natural structure which
identifies the possible states that patients may be in
and the effect of the interventions on these states; a
method of transforming the evidence into estimates of
costs and benefits for comparison; an assessment of
the uncertainty present in the comparison of interven-
tions; and identification of the value of future research
to further inform decisions [14].
Decision analytic models
Development of model structure is a crucial part of the
research process, the aim is to develop a model which is
no more complex than it needs to be to answer the
questions posed. They should be designed to represent
important outcomes and estimate the relevant costs and
health benefits, for each choice under consideration.
Decision trees and Markov models are two common
choices of models.
A simple decision tree is drawn in Figure 1. This
represents a hypothetical case of chronic heart failure
and treatment with current therapy and a new therapy
comprised of the current treatment, with CAM intro-
duced as a complement. It shows: a decision at the
square ‘decision node’, and this is where a decision to
adopt one therapy over the other is summarised; the
alternate events that might occur at the circular ‘chance
nodes’, which in this example are improvement or dete-
rioration; and the final cost and health benefits of every
possible pathway at the triangular ‘terminal nodes’.T h e
expected economic values arising from each decision are
the product of the final costs and health benefits and
the likelihood of the alternate events, known as prob-
abilities. The tree is rolled back from right to left.
Probabilities for a given treatment must sum to 1, in
this example for current therapy, the probability of
improvement is 0.6 and the probability of deterioration
is 0.4, summed together they equal 1. Probabilities are
based on available information which may come from a
variety of sources, including clinical trials, observational
studies, case series, expert opinion, or a secondary ana-
lysis of any of the above sources [26]. The probabilities
used and the quality of the data source will impact on
the analysis, sensitivity analysis is performed to assess
this impact [14].
T h e r ea r ear a n g eo fc o s t st oc o n s i d e r .T h e s ei n c l u d e
health system costs, such as drugs, hospitalisation,
equipment, medical staff; costs to other sectors; patient/
family costs, such as travel costs and time; and produc-
tivity costs, the effect of work time. The range of costs
included in the evaluation will depend upon the view-
point taken in the analysis. For example, travel costs
incurred by the patient and patient’s family members
and the cost of time away from work are likely to be
important from the point of view of the patient and
society, however, it is may not be as important to the
government [14]. There are two components of deter-
mining costs, the quantity of resources used and the
market price of the resources. For example, if we con-
sider the price of medication, conventional and CAM
approaches, for heart failure and the cost of an outpati-
ent visit to a medical practitioner, we must first estab-
lish what medications are taken, in what amounts and
their price, and then how many outpatient visits a per-
son with heart failure would have in addition to the
price of the visit, or some approximation of the price.
The information for this comes from a variety of
sources, including published cost data, administrative
databases, such as those held by the Australian Institute
of Health and Welfare (AIHW), previous economic eva-
luations and expert opinion [26].
Calculations of expected costs and outcomes from the
data drawn in Figure 1 are shown here:
Expected cost of current treatment = (0.6 × $500) +
(0.4 × $600) = $540
Expected cost of new treatment = (0.7 × $520) +
(0.3 × $620) = $550
Expected QALYs of current treatment = (0.6 × 10) +
(0.4 × 5) = 8
Expected QALYs of new treatment = (0.7 × 10) +
(0.3 × 5) = 8.5
Using the expected costs and benefits calculated,
shown in Table 1, an Incremental Cost Effectiveness
Ratio (ICER) can be calculated, which tells us the incre-
mental cost per additional QALY generated by the new
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competing treatments and provide information about
their value for money.
Calculation of the ICER = ($550-$540)/(8.5-8) = $20
per QALY.
Decision trees have limitations: time is not made
explicit, and they quickly become large and unwieldy
when dealing with long timeframes and multiple events,
becoming visually and computationally complex.
Markov models are an alternate approach to decision
analytic modelling and have added flexibility and are
suitable for more complex situations. There are a series
of mutually exclusive ‘states’ d r a w ni nF i g u r e2w h i c ha
patient can occupy at a given point in time instead of
branches in a decision tree. Time is represented expli-
citly, the probability of a patient being in a particular
s t a t ea tap a r t i c u l a rp o i n ti nt i m ei se x a m i n e do v e ra
series of cycles. Movement between the states is deter-
mined by the calculation of transition probabilities
which reflect ‘real life’ disease progression. Transition
probabilities capture the chance of maintaining the
same level of health, improvement, deterioration or
death.
CAM is often complex as wella so f t e nu s e db yt h o s e
with chronic disease and those seeking long-term pre-
vention. Markov models are ideally suited to complex
chronic disease and may be ideal for the economic eva-
luation of CAM due to the added flexibility and ability
to represent complex situations.
In Figure 2 we show the probability of a patient mov-
ing between states and remaining in states for each
cycle of the model for a ‘current treatment’ alternative.
This information is also shown as a transition matrix in
Table 2. Note that the sum of each row must add up to
1, and this ensures that no patient can leave the model.
Different values for the transition probabilities will be
used for alternate treatments that compete with the cur-
rent treatment. A new more effective treatment might
for example take a lower value for the probability of
moving from ‘Improvement to ‘Deterioration’ and from
‘Improvement’ to ‘Death’. This is shown in Table 3.
Under any competing treatment alternative the move-
ments of say 1,000 patients between health states over
time (cycles) can be summarised, in this case one cycle
lasts one year. Patient movements through the Markov
model are shown in Table 4 for the current treatment
probabilities, for the first three cycles. One thousand
patients are always retained in the model.
Each row of the table represents a cycle during which
time patients incur costs from treatment and accrue
Heart Failure 
Current Treatment 
 (Cost= $500, QALYs= 10)
(Cost= $600, QALYs= 5)
(Cost= $620, QALYs= 5)
(Cost= $520, QALYs= 10) 
Improvement (P= 0.6) 
 
Deterioration (P= 0.4) 
New Treatment 
Improvement (P= 0.7) 
Deterioration (P= 0.3) 
Figure 1 Example of a decision tree.
Table 1 Example of an ICER
Intervention Costs QALYs
Current $ 540 8
New $ 550 8.5
Difference $ 10 0.5
ICER $ 20 Per QALY
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number of patients in each state for each cycle has been
calculated, we can calculate the total costs and benefits
for a treatment option. We need to know the cost and
benefit associated with being in each state, which are
shown in Figure 2. To calculate costs for each cycle, the
number of patients in each state is multiplied by the
cost of that state and then summed for all the states for
that cycle. To calculate benefits for each cycle, the pro-
portion of patients in each state is multiplied by the uti-
lity value of each state and then summed for all the
states for that cycle.
The costs for current treatments in cycle 1 are (700*
$200) + (200*$250) + (100*$0) = $190,000. The health
benefits for cycle 1 are (700*0.8) + (200*0.5) + (100*0) =
660 QALYs. The total cost of three cycles (three years)
for the current treatment is $496,300 and total QALYs
is 1,652.2. When the new treatment probabilities are
used in the model the costs change to $513,550 and
total QALYs is 1782.7. As with the decision tree, an
ICER is then calculated (see Table 5).
Calculation of the ICER = ($513,550-496,300)/(1782.7-
1652.2) = $132.18 per QALY.
For both modelling approaches data are required to
inform probabilities of events under competing treat-
ment options and the costs and health outcomes that
arise. To identify the data that can be used to describe
the models parameters a process of evidence synthesis is
required.
evidence synthesis
Appropriate evidence for all parameters of the model
needs to be identified to ensure the reliability of the
model. The evidence base will consist of studies from
diverse sources and the quality of evidence differs
between studies. This is of particular relevance for
CAM, as there are often quality issues due to difficulties
with study design and the use of small samples. Evi-
dence needs to be systematically searched and identified,
and there are many documented methods for this [27].
Legend 
 
 
    = probability of remaining in state 
 
 
  
    = probability of moving to another state 
Improvement 
Cost = $200 
Utility Score = 0.8 
Deterioration 
Cost=$250 
Utility Score = 0.5 
Death 
Cost=$0 
Utility Score = 0 
P=0.20 
P=0.30 
P=0.50 
P=0.10 
P=0.70 
P=1.0 
Figure 2 Example of a Markov model.
Table 2 Example of a Transition Matrix (current
treatment)
transition matrix Improvement Deterioration Dead
Improvement 0.70 0.20 0.10
Deterioration 0.20 0.50 0.30
Dead 0.00 0.00 1.00
Table 3 Example of a Transition Matrix (new treatment)
transition matrix Improvement Deterioration Dead
Improvement 0.80 0.15 0.05
Deterioration 0.20 0.50 0.30
Dead 0.00 0.00 1.00
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controlled trials (RCTs), observational studies, cohort
studies, administrative databases, expert opinion, clinical
outcome registers, cost information, and routine
statistics.
Evidence synthesis, the process of bringing all the
information together, is a crucial step in the process of
economic evaluation and decision analytic modelling.
Meta-analysis is a common method for the synthesis of
quantitative data, providing a numerical summary of the
overall effectiveness of an intervention [28]. The quality
of data included in the model will determine the model
validity, especially when this data is used for parameters
which have a large influence on the model results.
Therefore transparency is vital when presenting the
methods of economic evaluation. The reader needs to
be able to see the data, the methods used for analysis
and the assumptions made, in order to make an
informed decision about model validity.
It is often argued that CAM is under-researched, and
when evidence exists it is often of poor quality. Whilst
the process of evidence synthesis and the ability to
incorporate multiple data sources of varying quality do
not replace rigorous research or negate the need to
expand the evidence base, they do provide an opportu-
nity to examine the current evidence base and use the
data available to make a decision. The adept modeller
will characterise the role of uncertainty in the decision
they are informing. Methods exist, that are beyond the
scope of this article, for describing uncertainty, and
should be used for any applied modelling study.
How information from models should be used by
decision makers
The results of cost-effectiveness data we found from the
Markov model analysis can be shown graphically using
the cost-effectiveness plane (see Figure 3). In this
diagram, the horizontal axis represents the difference in
effect between the intervention of interest and the alter-
native. The vertical axis represents the difference in cost
between the two interventions. The slope of the line
represents the ICER (refer to Table 5). In this case the
new treatment lands on a point in quadrant I (i.e., ‘A’)
the intervention is more costly and more effective, if it
lands on a point in quadrant II (ie., ‘B’)t h ei n t e r v e n t i o n
is less costly and more effective (it dominates the alter-
native), if it lands on a point in quadrant III (ie., ‘C’)t h e
intervention is less costly and less effective, and if it
lands on a point in quadrant IV (ie., ‘D’)i ti sm o r e
costly and less effective (it is dominated by the alterna-
tive intervention). If the intervention is located on a
point in quadrant I or quadrant III a decision must be
made as to whether the benefits of the more effective
intervention are worth the extra costs involved.
The situation where one intervention is more effective
and more costly than another occurs relatively often (ie.,
‘A’). If this occurs, the decision regarding whether the
benefits of the more costly intervention are worth the
extra costs will depend upon the threshold for the deci-
sion maker or the willingness-to-pay per unit of health
gain (such as per QALY or per life year). There are
many suggestions in the literature as to what constitutes
an appropriate threshold value, but in reality this is an
arbitrary figure and decision makers do not use such an
absolute threshold [29,30]. It is necessary to have some
threshold guidance for health care decisions, as the sup-
ply of new and effective technologies increases and the
access to health care improves, there will be increased
pressure on the health care budget which requires a
consistent method for determining which interventions
or therapies are worth funding [31]. The National Insti-
tute for Clinical Excellence (NICE) takes the view that
at £5000-£15 000/QALY interventions are likely to be
acceptable, at £25 000-£35 000/QALY special reasons
Table 4 Example of Markov model cycles (current
treatment)
Cycle Improvement Deterioration Dead Total
0 1000 0 0 1000
1 700 200 100 1000
2 530 240 230 1000
3 419 226 355 1000
Table 5 Example of an ICER for the Markov model
Intervention Costs QALYs
Current $496,300 1652.2
New $513,550 1782.7
Difference $17,250 130.5
ICER $132.18 per QALY
$17,250
A
ICER=$132.18
+ I
II III
IV
B C
D
New 
treatment 
more 
effective
New 
treatment 
less 
effective
New 
treatment 
more costly
New 
treatment 
less costly
130.5
Figure 3 Example of a cost effectiveness plane.
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are made on a case-by-case basis, and as the ICER
increases the likelihood of rejection also increases [32].
Along with production efficiency, decision makers
must consider affordability. A focus only on a threshold
w o u l dl e a dt oa ni n f i n i t ei n c r e a s ei nc o s t s .T h i si s
because many programmes, more than can be afforded,
may fall below a threshold. The economic reality is that
health resources are scarce and it may not be possible
to increase the health care budget, if we recommend an
option which increases costs, additional funds will have
to be taken from elsewhere and redirected toward the
new intervention. The cost of losing currently funded
programs must be known before any final decision is
made [33].
The results of economic evaluation are often not
incorporated into decision making. Reasons for this
include limited dissemination of the results, a lack of
recognition of the implications of the results, poor
understanding of the process of economic evaluation, a
lack of belief in the results, and a lack of political power
to enact change based on the results [14]. Where deci-
sions have been made based on the results of economic
evaluation, there are several factors taken into consid-
eration. A cost-effectiveness threshold is applied, above
which decisions are increasingly unlikely to be in favour
of adopting the intervention and below which the inter-
vention is usually adopted. Cost-effectiveness is consid-
ered in conjunction with the level of uncertainty
surrounding the results and the burden of the disease
under consideration. Social value judgements concerning
equity, fairness, and what is considered to be good for
society may also influence the decision [32].
It is clear that decisions in health care will always be
made in the midst of a complex interplay of political,
social and economic factors. However, economic evalua-
tion is used to inform decisions, for example, the Aus-
tralian breast and cervical screening programs were
developed in conjunction with economic evaluation [34].
Whilst currently mostly restricted to pharmaceuticals,
many jurisdictions now require economic evidence to
accompany funding requests. With requirements for this
evidence growing amidst scarce resources and fixed
health budgets, it is reasonable to assume that such evi-
dence will become an essential requirement for all inter-
ventions and therapies under consideration [35].
NICE in the United Kingdom is an organisation which
uses economic evaluation and cost-effectiveness as the
basis for decisions. The role of NICE is to provide
recommendations concerning which new and existing
technology should be funded by the National Health
Service (NHS). These recommendations are legally bind-
ing adding significant weight to implementation [36].
The Pharmaceutical Benefit Advisory Committee
(PBAC) performs a similar role in Australia for pharma-
ceuticals, and similarly the Medical Services Advisory
Committee (MASC) looks at medical technologies and
procedures. NICE has the advantage of being able to set
its own agenda and prioritise evaluation, as well as suc-
cessfully using a rapid response method, ideal when
answers are required within short timeframes [37].
what else influences the decision to accept CAM?
Rigorous research and economic evaluation of CAM is a
necessary step toward acceptance and adoption of these
medicines and therapies by health care decision makers.
Other issues, including historical and current public
acceptance and demand, practitioner acceptance (parti-
cularly conventional practitioners), as well as political
attitudes, will be influential in the decision to incorpo-
rate CAM into a comprehensive health care system.
Conventional practitioners and decision makers have to
date tended not to focus on CAM [38]. Different practi-
tioner’s beliefs and their exposure to and experience
with CAM therapies all play a role, and in a sense,
despite evidence of efficacy and effectiveness, CAM
therapies have to repeatedly demonstrate their value
[39]. Economic evaluation adds weight to the growing
evidence base for CAM and will make it harder for
CAM and its potential benefits to be overlooked in
health care provision and practice decision-making.
Conclusions
Economic evaluation is a decision-making tool for
informing clinical practice and health policy (aiding
informed decision-making regarding CAM and its inte-
gration into the health care system). The use of decision
analytic modelling as a method of economic evaluation
is a flexible method well suited to CAM as it does not
rely solely on RCTs, but combines multiple data sources
and can extrapolate beyond the limits of current clinical
evidence. Efficacy and cost-effectiveness must be estab-
lished and the results widely distributed in order for
CAM to be extensively considered in healthcare deci-
sion-making. Information about economic evaluation is
widely available, however, without any formal training
CAM practitioners may be challenged in an attempt to
utilise these economic evaluation methods. As with con-
temporary health research more generally, it is certainly
important that multidisciplinary teams be deployed in
order to share disciplinary insights and supplementary
research knowledge. One example of how such a multi-
disciplinary approach is being facilitated at a national
and international level is through initiatives of the Net-
work of Researchers in the Public Health of Comple-
mentary and Alternative Medicine (NORPHCAM).
NORPHCAM has established a health economics
research stream helping to introduce and facilitate inter-
national collaborations between health economists,
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interested in developing the economic evaluation of
CAM. Whether examining the use of CAM alone or as
an integrated component of contemporary health care
provision, further consideration of economic evaluation
as a research tool is required. This paper provides an
impetus for those interested to pursue such a worthy
goal.
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